Gilead Sciences GILD Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Total revenues by Product | |||||
| AmBisome | $509M-4.7% | $534M+8.3% | $493M-1.0% | $498M-7.8% | |
| Biktarvy | $14.33B+6.8% | $13.42B+13.3% | $11.85B+14.0% | $10.39B+20.5% | |
| Descovy | $2.76B+30.5% | $2.11B+6.4% | $1.99B+6.1% | $1.87B+10.1% | |
| Genvoya | $1.5B-15.0% | $1.76B-14.5% | $2.06B-14.3% | $2.4B-16.5% | |
| Odefsey | $1.17B-9.4% | $1.29B-4.7% | $1.35B-8.1% | $1.47B-6.3% | |
| Other HIV | $500M+15.2% | $434M+8.0% | $402M-24.2% | $530M— | |
| Other Liver Disease | $834M+79.0% | $466M+21.4% | $384M-9.9% | $426M— | |
| Other | $290M-18.5% | $356M-2.7% | $366M-18.5% | $449M+59.8% | |
| Royalty, contract and other revenues | $527M+269% | $143M-21.0% | $181M-39.5% | $299M+0.7% | |
| Sofosbuvir/Velpatasvir | $1.27B-20.2% | $1.6B+3.8% | $1.54B+0.5% | $1.53B— | |
| Symtuza - Revenue share | $495M-16.4% | $592M+11.9% | $529M-0.2% | $530M— | |
| Tecartus | $343M-14.9% | $403M+8.6% | $371M+24.1% | $299M+69.9% | |
| Trodelvy | $1.4B+6.2% | $1.32B+23.7% | $1.06B+56.5% | $680M+78.9% | |
| Veklury | $911M-49.4% | $1.8B-17.6% | $2.18B-44.1% | $3.91B-29.8% | |
| Vemlidy | $1.07B+11.6% | $960M+11.2% | $863M+2.4% | $843M+3.6% | |
| Yescarta | $1.5B-4.7% | $1.57B+4.8% | $1.5B+29.1% | $1.16B+66.9% | |
| Total revenues by Geography | |||||
| Europe | $5.06B+9.3% | $4.63B+7.5% | $4.31B-3.6% | $4.47B-8.3% | |
| Rest of World | $3.5B-0.7% | $3.53B+4.8% | $3.37B-14.3% | $3.93B— | |
| U.S. | $20.88B+1.4% | $20.59B+5.9% | $19.44B+2.9% | $18.88B-2.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Gilead Sciences break its business down?
- Gilead Sciences (GILD) reports total revenues by product across 18 parts — AmBisome, Biktarvy, Descovy, Genvoya and Livdelzi. Each is extracted from the segment footnotes and tracked over time.
- Where does Gilead Sciences's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Gilead Sciences's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
